AbbVie (ABBV) Short-term Investments (2012 - 2025)

AbbVie (ABBV) has reported Short-term Investments for 14 consecutive years, with $28.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Short-term Investments fell 9.68% year-over-year to $28.0 million; the TTM figure through Dec 2025 stood at $28.0 million (down 9.68% YoY), while the FY2025 annual figure was $28.0 million, down 9.68% from the prior year.
• Short-term Investments fell to $28.0 million in Q4 2025 per ABBV's latest filing, from $42.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $1.5 billion in Q1 2022 and bottomed at $1.0 million in Q1 2025.
• Historically, Short-term Investments has averaged $178.8 million across 5 years, with a median of $28.0 million in 2022.
• Annual changes were most pronounced in 2022 — Short-term Investments soared 6600.0% — and 2023, when it plunged 99.51%.
• AbbVie's Short-term Investments stood at $84.0 million in 2021, then slumped by 66.67% to $28.0 million in 2022, then sank by 92.86% to $2.0 million in 2023, then soared by 1450.0% to $31.0 million in 2024, then retreated by 9.68% to $28.0 million in 2025.
• Business Quant data shows ABBV's Short-term Investments at $28.0 million in Q4 2025, $42.0 million in Q3 2025, and $1.0 million in Q1 2025.